close

HVTN 100 Clinical Trial Findings Advance HIV Vaccine Research and Development

An HIV vaccine regimen tested in an early-phase clinical trial elicited robust immune responses that appeared to be stronger than those observed in a landmark 2009 study showing that a vaccine can protect people from HIV infection.  These findings from the ongoing Phase I/II HVTN 100 study were published on June 10 in Lancet HIV.

The trial studied a vaccine regimen designed to improve upon the one used in the 2009 study, the U.S. Military HIV Research Program-led RV144 trial in Thailand, the only study to-date to show protection, albeit modest, in humans.

To read more click here

HVTN 100 Clinical Trial Findings

HVTN 100 Clinical Trial Findings

HVTN 100 Clinical Trial Findings

HVTN 100 Clinical Trial Findings